Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s): CRDL

Healthcare

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.

TSX:CRDL - Post by User

Cardiol Therapeutics Inc

Bullboard Posts

Post by Myceliumon Jul 17, 2020 12:19am

177 Views

Post# 31279524

Shopper's deal

In reality, and this was brought up some time ago, is the Shopper's deal going to net the company much income? Has anyone got any idea of what sort of revenue one might expect?
I believe it's in it's ability to fight heart failure and myocarditis with it's unique product, that the company stock will flourish, such as GWPH or MYOK have done.
I am a believer, and I am accumulating, at these levels but to get to a Phase 2 trial will take a long time.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload